FREEDOM HOLDING CORP. (FRHC): what the price requires
The current priced-in claim for FREEDOM HOLDING CORP. (FRHC) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/FRHC
Headline
| Field | Value |
|---|---|
| Ticker | FRHC |
| Company | FREEDOM HOLDING CORP. |
| Current price | $161.87/sh |
| Composition | Brokerage 41% / Banking 34% / Insurance 25% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | financials |
| Price-to-book | 6.66x |
The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The rarity read below is the honest signal.
How unusual the bet is: extreme
| Reference | Value |
|---|---|
| vs own history | +1.80σ |
| cohort percentile (of 72 peers) | 78 |
| sustained it ~10 years at this level | 24% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 5.64x | 4 | expensive |
| Earnings | 4.88x | 2 | expensive |
| Relative | 3.79x | 4 | expensive |
| Growth | 4.36x | 2 | expensive |
Families that call it expensive: Asset, Earnings, Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.0%); the inversion above states its own rate.
Per-Model Detail (n=12)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $21.43 | 7.55x | yes | Reference only (OCF-based, capex excluded): OCF $0.2B |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $73.39 | 2.21x | yes | P/E 26.4x (blended: static sector reference 12x + trailing (TTM) 65x), scenarios: 21.8x / 26.4x / 31.0x (bear / base = reference held flat / bull), EV/EBITDA N/Ax |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $27.12 | 5.97x | yes | BV/sh $24.37, ROE (TTM) 10.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $28.57 | 5.67x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $138.39 | 1.17x | yes | Rev $2.2B, growth 11% (input: historical growth; tapered), Terminal P/S: 3.7x / 4.5x / 5.3x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $30.12 | 5.37x | yes | EPS $2.51, growth 6% (input: historical EPS growth), PEG=10.99 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | $28.83 | 5.61x | yes | BV $24.37 + 5yr PV of (ROE (TTM) 10.3% − Kₑ 9.3%) × BV; BV grows 6.7%/yr |
| Graham Number | Asset | $37.10 | 4.36x | yes | √(22.5 × EPS $2.51 × BVPS $24.37) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $42.58 | 3.80x | yes | EPS $2.51 × (8.5 + 2×5.9%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $107.57 | 1.50x | yes | Revenue $2.19B × sector P/S 3.0x |
| PEG Fair Value | Relative | $22.10 | 7.32x | yes | EPS $2.51 × (PEG 1.5 × growth 5.9% (input: historical EPS growth)) → PE 8.8x |
| Earnings Yield | Earnings | $27.14 | 5.96x | yes | EPS $2.51 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Share count CAGR (dilution) | 0.6% |
Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).
Bullet Takeaways
- Freedom Holding is a multinational financial services group spanning brokerage, banking, and insurance, anchored in Central Asia, and it just doubled net income to $153.3 million on record revenue of $2.19 billion in fiscal 2026.
- The price requires a return on equity near 38% to make sense against book value, while the business has earned closer to 10% on a trailing basis, so the central risk is simply that the gap between what the price assumes and what the company earns is enormous.
- Watch the durability of trading gains: fiscal 2026 net gains on trading securities jumped to $158.8 million largely from sales of Kazakhstan sovereign and corporate debt, a source that can reverse as fast as it appeared.
Bull Case
Look first at the balance sheet, because it tells you what management actually believes. Freedom Holding's banking segment closed fiscal 2026 with combined assets of $5.36 billion, up 21% in a year, a loan book up 29% to $2.05 billion, and a deposit base up 46% to $2.52 billion. Deposits growing faster than loans is the sign of a franchise winning customer trust rather than reaching for risky assets to fund itself. Banking customers more than doubled, from 2.52 million to 5.03 million. This is a company aggressively building a regional financial network and funding it with cheap, sticky customer money rather than expensive wholesale borrowing. Equity is compounding alongside it.
The growth is real and it is broad. Brokerage customers rose from 683,000 to 858,000, continuing a multi-year climb the 10-K traces back through its earlier expansion, when retail brokerage accounts grew "from 530,000 in 2024 to 683,000 in 2025. Freedom reports through brokerage, banking, and insurance segments, and the diversification matters: when one line slows, another can carry. Fiscal 2026 net income doubled to $153.3 million on revenue that reached a record $2.19 billion, the kind of operating leverage that emerges when a financial platform scales across a fixed cost base. The company now operates across more than twenty countries, building an integrated brokerage-bank-insurance offering in markets where incumbents are weaker and digital-first competitors are scarce.
That last point is the structural bet. In developed markets, a brokerage or a bank fights for share against deep-pocketed incumbents. In the emerging markets where Freedom is concentrated, the company is closer to building the rails than renting them, capturing customers as financial participation deepens across a growing middle class. If the firm sustains even a fraction of the customer growth it has shown, the deposit and brokerage franchise compounds on itself, and the return on equity follows the scale. The bull case is that you are buying the early innings of a financial network in markets that are still forming.
Bear Case
The structural truth a holder would rather not face is this: the multiples are pricing growth that has not yet shown up in returns. At $143.98 (June 27, 2026), the stock trades at roughly six times its book value of $24.37 per share. A price-to-book that high is only justified by a high and durable return on equity, because book value is what the bank actually owns and the multiple is the market's bet on how fast that equity compounds. Freedom's trailing return on equity is about 10.3%, barely above its estimated cost of equity near 9.3%. To support six times book, the price requires a return on equity closer to 38%, sustained for years. No standard valuation method reaches the current price. The asset-based methods land near $28, the earnings-power methods near $27, and even the forward-growth methods fall short. That is not a small premium; it is a price beyond what any conventional frame supports.
The quality of the earnings is the second problem. A large share of the fiscal 2026 profit came from net gains on trading securities of $158.8 million, which the company attributes primarily to sales of Kazakhstan sovereign and corporate debt. Trading gains are not recurring fee income; they swing with markets and with the firm's own positioning. The volatility is visible in the company's own history: the 10-K notes a prior-year net loss on trading securities of $57.8 million. A business whose bottom line can flip from a large trading loss to a large trading gain year to year does not have the earnings stability that a six-times-book multiple implies. Strip the trading windfall and the underlying return on equity looks even thinner.
Then there is the structure of the company itself. The 10-K discloses dependence on related-party arrangements, warning that "there is no assurance that we will be able to replace these related-party arrangements on comparable terms if needed. If we are required to pursue alternative options, we may incur higher costs, delays, or operational inefficiencies. Concentration in Kazakhstan and neighboring markets layers currency, political, and regulatory risk on top, and the filing flags exposure to "the impact of legal and regulatory actions, investigations and disputes. For a financial firm, capital and counterparty trust are the entire business. A premium price built on a 10% return, propped up by volatile trading gains and intertwined with related parties, is a fragile combination.
Valuation
The price is betting on a transformation in profitability, not on the business as it currently earns. For a financial company, the relevant lens is return on equity against the multiple of book value, and here the two are far apart. The stock trades near six times its book value of $24.37 per share, a multiple that mathematically requires a return on equity of roughly 38% to be warranted. The company's trailing return on equity is about 10.3%, only modestly above its cost of equity. That gap is the whole valuation.
What makes this case unusual is that no family of methods reaches the price. Typically at least one lens, often forward growth, can rationalize a high quote. Here the asset-based methods, built from book value and the excess return earned on it, cluster near $28. The earnings-power methods, capitalizing trailing earnings, land around $27. The relative-multiple methods are mixed but mostly well below the price, with a sales-based read reaching the low-$100s only by applying a sector price-to-sales multiple to $2.19 billion of revenue. Even the forward-growth methods, which credit continued expansion, barely reach the price in one optimistic case and fall short elsewhere. When every family says expensive, the price is a bet beyond what standard analysis supports, and the burden of proof sits entirely on future returns rising far above what the firm has demonstrated.
Solvency for a financial is read through regulatory capital and the stability of funding, not net debt or cash burn, because deposits are funding rather than corporate leverage and operating cash flow tracks loan flows. On that frame Freedom looks well-funded: deposits grew 46% to $2.52 billion and now exceed the loan book, share count has been essentially flat, and equity is compounding with earnings. The funding side is not the worry. The worry is earnings quality and the distance between a 10% demonstrated return and the near-40% the price assumes. Until the return on equity moves durably higher, on recurring fee income rather than trading gains, the valuation rests on faith.
Catalysts
Freedom Holding reported fiscal 2026 results in early June, with revenue of a record $2.19 billion against $2.00 billion the prior year, and net income more than doubling to $153.3 million from $76.2 million. The single largest swing factor was net gain on trading securities of $158.8 million, an increase of $216.6 million year over year, which the company attributes primarily to sales of Kazakhstan sovereign and corporate debt securities. That is the number to watch most closely, because it is both the reason earnings doubled and the least repeatable part of the result.
The operating franchise grew across segments. Brokerage customers rose from 683,000 to 858,000, and banking customers doubled from 2.52 million to 5.03 million. The banking segment ended the year with combined assets of $5.36 billion, up 21%, a loan portfolio up 29% to $2.05 billion, and deposits up 46% to $2.52 billion. The customer and deposit momentum is the recurring story underneath the one-time trading gain.
For the next several quarters, the key reads are whether fee-based and net-interest income can grow into the gap left if trading gains normalize, and whether the firm's exposure to Central Asian markets and related-party arrangements draws any regulatory attention. The next earnings report will show how much of the fiscal 2026 jump was structural and how much was the bond-trading windfall.
Peer Cohorts (Per Segment, With Filing Citations)
Brokerage (reported)
- IBKR (INTERACTIVE BROKERS GROUP, INC.)
- (no filing in the citation store)
- HOOD (Robinhood Markets Inc)
- (no filing in the citation store)
- SCHW (SCHWAB CHARLES CORP)
- (no filing in the citation store)
- LPLA (LPL Financial Holdings Inc.)
- (no filing in the citation store)
- VIRT (Virtu Financial, Inc.)
- (no filing in the citation store)
- PIPR (PIPER SANDLER COMPANIES)
- (no filing in the citation store)
- SF (STIFEL FINANCIAL CORP)
- (no filing in the citation store)
- RJF (RAYMOND JAMES FINANCIAL INC)
- (no filing in the citation store)
Banking (reported)
- FCNCA (FIRST CITIZENS BANCSHARES INC /DE/)
- (no filing in the citation store)
- EWBC (EAST WEST BANCORP INC)
- (no filing in the citation store)
- CFG (CITIZENS FINANCIAL GROUP INC/RI)
- (no filing in the citation store)
- RF (Regions Financial Corporation)
- (no filing in the citation store)
- WBS (WEBSTER FINANCIAL CORPORATION)
- (no filing in the citation store)
- CFR (Cullen/Frost Bankers, Inc.)
- (no filing in the citation store)
- WAL (WESTERN ALLIANCE BANCORPORATION)
- (no filing in the citation store)
- ZION (ZIONS BANCORPORATION, NATIONAL ASSOCIATION)
- (no filing in the citation store)
Insurance (reported)
- CINF (CINCINNATI FINANCIAL CORPORATION)
- (no filing in the citation store)
- KMPR (Kemper Corporation)
- (no filing in the citation store)
- HIG (The Hartford Insurance Group, Inc.)
- (no filing in the citation store)
- AFG (AMERICAN FINANCIAL GROUP, INC.)
- (no filing in the citation store)
- ORI (OLD REPUBLIC INTERNATIONAL CORP)
- (no filing in the citation store)
- THG (HANOVER INSURANCE GROUP, INC.)
- (no filing in the citation store)
- HMN (HORACE MANN EDUCATORS CORPORATION)
- (no filing in the citation store)
- MCY (MERCURY GENERAL CORP)
- (no filing in the citation store)
Other (reported)
- VIRT (Virtu Financial, Inc.)
- (no filing in the citation store)
- PIPR (PIPER SANDLER COMPANIES)
- (no filing in the citation store)
- SF (STIFEL FINANCIAL CORP)
- (no filing in the citation store)
- HOOD (Robinhood Markets Inc)
- (no filing in the citation store)
- BGC (BGC Group, Inc.)
- (no filing in the citation store)
- TW (Tradeweb Markets Inc.)
- (no filing in the citation store)
- NDAQ (Nasdaq, Inc.)
- (no filing in the citation store)
- ICE (Intercontinental Exchange Inc)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
FY2026 results, June 2026 · FY2026 results release, June 2026